← 返回

基于颗粒酶 B、靶向膜结合 HSP70 的 CAR-T 细胞抑制实体瘤生长与转移

英文原题:Granzyme B-based CAR-T cells targeting membrane-bound HSP70 suppress solid tumor growth and metastasis.

查看英文原题

Granzyme B-based CAR-T cells targeting membrane-bound HSP70 suppress solid tumor growth and metastasis.

PubMed 2026/04/18(内容时间) Oncogene Q1 · IF 9.1(JCR 2025)

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

中文摘要

利用CAR-T 细胞清除循环肿瘤细胞(CTCs)并抑制转移是一种有前景的策略。然而,该方法因缺乏特异性抗原而受到限制。膜结合型HSP70(mHSP70)通常表达于多种肿瘤类型的细胞膜上,尤其是CTCs上,使其成为CAR-T 治疗此类恶性肿瘤并预防转移的理想靶点。

在此,我们基于天然配体颗粒酶B(GrB-CAR-T)构建了靶向mHSP70的CAR-T 细胞。GrB-CAR-T 细胞在体外对广谱癌细胞系及干细胞样癌细胞表现出强效细胞毒性,并在体内有效抑制异种移植瘤生长。

重要的是,CTCs在异种移植模型中维持mHSP70表达,GrB-CAR-T 细胞显著减少了CTCs数量,从而预防癌症转移。

此外,尽管人颗粒酶B与小鼠和猕猴mHSP70存在交叉反应——尤其是鉴于猕猴与人的mHSP70完全同源——在接受GrB-CAR-T 细胞治疗的动物中未观察到明显的不良反应。这些结果表明,GrB-CAR-T 细胞是一种安全有效、具有广谱抗癌活性的方法,并为CAR-T 细胞通过靶向CTCs介导的转移抑制提供了有力的实验证据。

展开英文摘要原文

Utilizing CAR-T cells to eliminate circulating tumor cells (CTCs) and inhibit metastasis is a promising strategy.

However, this approach is hindered by the lack of specific antigens. Membrane-bound HSP70 (mHSP70) is commonly expressed on the cell membrane of numerous tumor types, notably on CTCs, making it an ideal target for CAR-T therapy to treat these malignancies and prevent metastasis.

Here, we generated CAR T cells based on natural ligand granzyme B (GrB-CAR T) targeting mHSP70. GrB-CAR T cells exhibited potent cytotoxicity against a broad spectrum of cancer cell lines and stem-like cancer cells in vitro and effectively inhibited xenograft tumor growth in vivo.

Importantly, CTCs maintain mHSP70 expression in xenograft models, and GrB-CAR T cells markedly decreased the number of CTCs, thereby preventing cancer metastasis.

Moreover, despite human granzyme B exhibits cross-reactivity with mouse and macaque mHSP70-particularly given the complete homology between macaque and human mHSP70-no obvious adverse effects were observed in the animals treated with GrB-CAR T cells. These results demonstrate GrB-CAR T cells as a safe and effective approach with broad-spectrum anticancer activity and provide compelling experimental evidence for CAR T cell-mediated metastasis inhibition through targeting CTCs.

论文信息

作者
Sun B、Guo J、Yang D、Hu Q、Ma H、Tian P、Liu N、Lv L
第一作者单位
Division of Abdominal Tumor Multimodality Treatment and Laboratory of Cell Engineering and Immunotherapy, Cancer Center and State Key Laboratory of Respiratory Health and Multimorbidity, Frontiers Science Center for Disease-Related Molecular Network, West China Hospital, Sichuan University, Chengdu, China.China
通讯作者单位
Division of Abdominal Tumor Multimodality Treatment and Laboratory of Cell Engineering and Immunotherapy, Cancer Center and State Key Laboratory of Respiratory Health and Multimorbidity, Frontiers Science Center for Disease-Related Molecular Network, West China Hospital, Sichuan University, Chengdu, China. zhaoxudong@wchscu.cn.China
期刊
Oncogene2026 Jun
原文标识
PubMed 42000923 · DOI 10.1038/s41388-026-03797-7